ZIM Laboratories Limited (BOM:541400)
India · Delayed Price · Currency is INR 75.64
-0.99 (-1.29%)
At close: Feb 12, 2026
ZIM Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 3,779 | 3,790 | 3,674 | 3,985 | 3,334 | 3,073 |
Other Revenue | 1.02 | 1.02 | 0.93 | 0.82 | 0.82 | 0.82 |
| 3,780 | 3,791 | 3,675 | 3,986 | 3,335 | 3,073 | |
Revenue Growth (YoY) | -2.65% | 3.16% | -7.80% | 19.52% | 8.51% | 10.63% |
Cost of Revenue | 1,745 | 1,758 | 1,815 | 2,072 | 1,670 | 1,635 |
Gross Profit | 2,035 | 2,033 | 1,860 | 1,914 | 1,665 | 1,438 |
Selling, General & Admin | 657.2 | 636.43 | 554.67 | 514.55 | 414.78 | 368.46 |
Other Operating Expenses | 972.86 | 928.78 | 877.91 | 871.97 | 839.1 | 664.69 |
Operating Expenses | 1,853 | 1,788 | 1,603 | 1,561 | 1,415 | 1,198 |
Operating Income | 182.09 | 245.73 | 256.66 | 352.59 | 250.31 | 240.55 |
Interest Expense | -108.85 | -94.72 | -58.82 | -49.7 | -71.69 | -95.1 |
Interest & Investment Income | 3.33 | 3.33 | 1.36 | 3.43 | 2.9 | 6.87 |
Currency Exchange Gain (Loss) | 41.44 | 41.44 | 38.06 | 55.49 | 38.54 | 13.94 |
Other Non Operating Income (Expenses) | -2.85 | -14.31 | -0.68 | -1.66 | -9.6 | -12.15 |
EBT Excluding Unusual Items | 115.17 | 181.47 | 236.58 | 360.15 | 210.46 | 154.12 |
Gain (Loss) on Sale of Assets | - | - | -0.16 | - | - | - |
Asset Writedown | -1.37 | -1.37 | - | -6.6 | -0.03 | - |
Other Unusual Items | - | - | - | - | - | -51.81 |
Pretax Income | 113.79 | 180.09 | 236.42 | 353.55 | 210.43 | 102.31 |
Income Tax Expense | 43.97 | 58.44 | 63.96 | 109.21 | 64.92 | 29.14 |
Earnings From Continuing Operations | 69.83 | 121.65 | 172.46 | 244.35 | 145.5 | 73.18 |
Minority Interest in Earnings | 0 | 0 | 0 | - | - | - |
Net Income | 69.83 | 121.65 | 172.46 | 244.35 | 145.5 | 73.18 |
Net Income to Common | 69.83 | 121.65 | 172.46 | 244.35 | 145.5 | 73.18 |
Net Income Growth | -54.56% | -29.46% | -29.42% | 67.93% | 98.84% | 121.97% |
Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | 49 |
Shares Outstanding (Diluted) | 49 | 49 | 49 | 49 | 49 | 49 |
Shares Change (YoY) | -0.31% | - | - | - | 0.09% | -0.01% |
EPS (Basic) | 1.43 | 2.50 | 3.54 | 5.01 | 2.99 | 1.50 |
EPS (Diluted) | 1.43 | 2.50 | 3.54 | 5.01 | 2.99 | 1.50 |
EPS Growth | -54.41% | -29.46% | -29.35% | 67.77% | 99.08% | 121.66% |
Free Cash Flow | - | 3.57 | -576.45 | 15 | 339.81 | 253.74 |
Free Cash Flow Per Share | - | 0.07 | -11.83 | 0.31 | 6.97 | 5.21 |
Gross Margin | 53.84% | 53.63% | 50.60% | 48.01% | 49.93% | 46.80% |
Operating Margin | 4.82% | 6.48% | 6.98% | 8.85% | 7.51% | 7.83% |
Profit Margin | 1.85% | 3.21% | 4.69% | 6.13% | 4.36% | 2.38% |
Free Cash Flow Margin | - | 0.09% | -15.68% | 0.38% | 10.19% | 8.26% |
EBITDA | 343.84 | 395.56 | 390.59 | 499 | 387.91 | 380.7 |
EBITDA Margin | 9.10% | 10.43% | 10.63% | 12.52% | 11.63% | 12.39% |
D&A For EBITDA | 161.75 | 149.83 | 133.94 | 146.41 | 137.6 | 140.14 |
EBIT | 182.09 | 245.73 | 256.66 | 352.59 | 250.31 | 240.55 |
EBIT Margin | 4.82% | 6.48% | 6.98% | 8.85% | 7.51% | 7.83% |
Effective Tax Rate | 38.64% | 32.45% | 27.05% | 30.89% | 30.85% | 28.48% |
Revenue as Reported | 3,848 | 3,848 | 3,726 | 4,049 | 3,378 | 3,096 |
Advertising Expenses | - | 25.39 | 19.11 | 19.14 | 9.03 | 7.96 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.